Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is a pervasive and persistent threat that requires the development of novel therapies or adjuvants for existing ones. Aptamers, small single-stranded oligonucleotides that form 3D structures and can bind to target molecules, provi...
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | English |
| Publicado: |
MDPI AG
2023-07-01
|
| Series: | Microorganisms |
| Subjects: | |
| Acceso en liña: | https://www.mdpi.com/2076-2607/11/7/1776 |
| _version_ | 1827732286907351040 |
|---|---|
| author | Matthew K. Doherty Claire Shaw Leslie Woods Bart C. Weimer |
| author_facet | Matthew K. Doherty Claire Shaw Leslie Woods Bart C. Weimer |
| author_sort | Matthew K. Doherty |
| collection | DOAJ |
| description | Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is a pervasive and persistent threat that requires the development of novel therapies or adjuvants for existing ones. Aptamers, small single-stranded oligonucleotides that form 3D structures and can bind to target molecules, provide one possible therapeutic route, especially when presented in combination with current antibiotic applications. BALB/c α-1, 3-galactosyltransferase (−/−) knockout (GTKO) mice were infected with MRSA via tail vein IV and subsequently treated with the αSA31 aptamer (n = 4), vancomycin (n = 12), or αSA31 plus vancomycin (n = 12), with split doses in the morning and evening. The heart, lungs, liver, spleen, and kidneys were harvested upon necropsy for histological and qPCR analysis. All mice treated with αSA31 alone died, whereas 5/12 mice treated with vancomycin alone and 7/12 mice treated with vancomycin plus αSA31 survived the course of the experiment. The treatment of MRSA-infected mice with Vancomycin and an adjuvant aptamer αSA31 reduced disease persistence and dispersion as compared to treatment with either vancomycin SA31 alone, indicating the combination of antibiotic and specifically targeted αSA31 aptamer could be a novel way to control MRSA infection. The data further indicate that aptamers may serve as a potential therapeutic option for other emerging antibiotic resistant pathogens. |
| first_indexed | 2024-03-11T00:49:25Z |
| format | Article |
| id | doaj.art-fd7b4829c29b4b45b295d6b0e0d9d20a |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-11T00:49:25Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-fd7b4829c29b4b45b295d6b0e0d9d20a2023-11-18T20:36:17ZengMDPI AGMicroorganisms2076-26072023-07-01117177610.3390/microorganisms11071776Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In VivoMatthew K. Doherty0Claire Shaw1Leslie Woods2Bart C. Weimer3Population Health and Reproduction, University of California Davis, Davis, CA 95616, USAPopulation Health and Reproduction, University of California Davis, Davis, CA 95616, USACalifornia Animal Health and Food Safety Laboratory, University of California Davis, Davis, CA 95616, USAPopulation Health and Reproduction, University of California Davis, Davis, CA 95616, USAMethicillin-resistant <i>Staphylococcus aureus</i> (MRSA) is a pervasive and persistent threat that requires the development of novel therapies or adjuvants for existing ones. Aptamers, small single-stranded oligonucleotides that form 3D structures and can bind to target molecules, provide one possible therapeutic route, especially when presented in combination with current antibiotic applications. BALB/c α-1, 3-galactosyltransferase (−/−) knockout (GTKO) mice were infected with MRSA via tail vein IV and subsequently treated with the αSA31 aptamer (n = 4), vancomycin (n = 12), or αSA31 plus vancomycin (n = 12), with split doses in the morning and evening. The heart, lungs, liver, spleen, and kidneys were harvested upon necropsy for histological and qPCR analysis. All mice treated with αSA31 alone died, whereas 5/12 mice treated with vancomycin alone and 7/12 mice treated with vancomycin plus αSA31 survived the course of the experiment. The treatment of MRSA-infected mice with Vancomycin and an adjuvant aptamer αSA31 reduced disease persistence and dispersion as compared to treatment with either vancomycin SA31 alone, indicating the combination of antibiotic and specifically targeted αSA31 aptamer could be a novel way to control MRSA infection. The data further indicate that aptamers may serve as a potential therapeutic option for other emerging antibiotic resistant pathogens.https://www.mdpi.com/2076-2607/11/7/1776antimicrobialMRSAaptamer antibioticantimicrobial resistancesepsis |
| spellingShingle | Matthew K. Doherty Claire Shaw Leslie Woods Bart C. Weimer Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo Microorganisms antimicrobial MRSA aptamer antibiotic antimicrobial resistance sepsis |
| title | Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo |
| title_full | Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo |
| title_fullStr | Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo |
| title_full_unstemmed | Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo |
| title_short | Alpha-Gal Bound Aptamer and Vancomycin Synergistically Reduce <i>Staphylococcus aureus</i> Infection In Vivo |
| title_sort | alpha gal bound aptamer and vancomycin synergistically reduce i staphylococcus aureus i infection in vivo |
| topic | antimicrobial MRSA aptamer antibiotic antimicrobial resistance sepsis |
| url | https://www.mdpi.com/2076-2607/11/7/1776 |
| work_keys_str_mv | AT matthewkdoherty alphagalboundaptamerandvancomycinsynergisticallyreduceistaphylococcusaureusiinfectioninvivo AT claireshaw alphagalboundaptamerandvancomycinsynergisticallyreduceistaphylococcusaureusiinfectioninvivo AT lesliewoods alphagalboundaptamerandvancomycinsynergisticallyreduceistaphylococcusaureusiinfectioninvivo AT bartcweimer alphagalboundaptamerandvancomycinsynergisticallyreduceistaphylococcusaureusiinfectioninvivo |